BR112017018963A2 - método para tratar anemia por deficiência de ferro - Google Patents

método para tratar anemia por deficiência de ferro

Info

Publication number
BR112017018963A2
BR112017018963A2 BR112017018963A BR112017018963A BR112017018963A2 BR 112017018963 A2 BR112017018963 A2 BR 112017018963A2 BR 112017018963 A BR112017018963 A BR 112017018963A BR 112017018963 A BR112017018963 A BR 112017018963A BR 112017018963 A2 BR112017018963 A2 BR 112017018963A2
Authority
BR
Brazil
Prior art keywords
deficiency anemia
iron deficiency
iron
patients
colitis
Prior art date
Application number
BR112017018963A
Other languages
English (en)
Portuguese (pt)
Inventor
Poradosu Enrique
Bentsur Ron
David SHEMESH Shay
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of BR112017018963A2 publication Critical patent/BR112017018963A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112017018963A 2015-03-04 2016-03-03 método para tratar anemia por deficiência de ferro BR112017018963A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562127963P 2015-03-04 2015-03-04
PCT/US2016/020575 WO2016141124A1 (en) 2015-03-04 2016-03-03 Use of ferric citrate in the treatment of iron-deficiency anemia

Publications (1)

Publication Number Publication Date
BR112017018963A2 true BR112017018963A2 (pt) 2018-05-15

Family

ID=56848619

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018963A BR112017018963A2 (pt) 2015-03-04 2016-03-03 método para tratar anemia por deficiência de ferro

Country Status (15)

Country Link
US (2) US20180071243A1 (cg-RX-API-DMAC7.html)
EP (1) EP3265077A4 (cg-RX-API-DMAC7.html)
JP (2) JP2018507260A (cg-RX-API-DMAC7.html)
KR (1) KR20170123664A (cg-RX-API-DMAC7.html)
CN (1) CN107530310A (cg-RX-API-DMAC7.html)
AU (1) AU2016226250B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017018963A2 (cg-RX-API-DMAC7.html)
CA (1) CA2978073A1 (cg-RX-API-DMAC7.html)
EA (1) EA201791960A1 (cg-RX-API-DMAC7.html)
HK (2) HK1248589A1 (cg-RX-API-DMAC7.html)
IL (1) IL254125A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017011169A (cg-RX-API-DMAC7.html)
SG (1) SG11201707120PA (cg-RX-API-DMAC7.html)
TW (2) TW202302083A (cg-RX-API-DMAC7.html)
WO (1) WO2016141124A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
US20210085711A1 (en) * 2017-09-19 2021-03-25 Japan Tobacco Inc. Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
FR3075601A1 (fr) * 2017-12-21 2019-06-28 Clarisse Le Court Complements alimentaires et leur utilisation sur les menstruations
US12467933B2 (en) 2019-06-07 2025-11-11 Arizona Board Of Regents On Behalf Of Arizona State University Body fluid iron level panel analyzer
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
WO2023047424A1 (en) * 2022-04-29 2023-03-30 West Bengal Chemical Industries Limited Pharmaceutical acceptable iron (iii) coordination complex having high phosphate binding capacity and preparation thereof
KR102623739B1 (ko) * 2022-07-28 2024-01-11 주식회사 페라메드 시트르산과 철을 포함하는 착화합물 및 그를 포함하는 식품 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) * 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
JP4931352B2 (ja) * 2004-01-14 2012-05-16 月桂冠株式会社 鉄補給剤及びその利用
CA2552889A1 (en) * 2004-01-14 2005-07-28 Sachiko Suzuki Iron supplement and utilization of the same
NZ566743A (en) * 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
WO2012097155A1 (en) * 2011-01-14 2012-07-19 Chiasma Inc. Improved pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
HK1246649A1 (zh) 2018-09-14
TW202302083A (zh) 2023-01-16
JP2018507260A (ja) 2018-03-15
KR20170123664A (ko) 2017-11-08
WO2016141124A1 (en) 2016-09-09
CN107530310A (zh) 2018-01-02
EP3265077A1 (en) 2018-01-10
HK1248589A1 (zh) 2018-10-19
EP3265077A4 (en) 2018-10-24
TW201639558A (zh) 2016-11-16
TWI812580B (zh) 2023-08-21
EA201791960A1 (ru) 2018-01-31
US20240075006A1 (en) 2024-03-07
SG11201707120PA (en) 2017-09-28
CA2978073A1 (en) 2016-09-09
MX2017011169A (es) 2017-11-09
JP2021091686A (ja) 2021-06-17
AU2016226250A1 (en) 2017-09-28
IL254125A0 (en) 2017-10-31
US20180071243A1 (en) 2018-03-15
AU2016226250B2 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112019009256A2 (pt) métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
MX2019005300A (es) Polimeros enlazados al proton para administracion oral.
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
EA201791960A1 (ru) Применение лимоннокислого железа в лечении вызванной недостатком железа анемии
MX2021004558A (es) Polimeros de union a protones para administracion oral.
BR112017011900A2 (pt) tratamento de ataques com fosfatase alcalina recombinante
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
DOP2016000102A (es) (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
BR112018012237A2 (pt) conjugados oligonucleotídeos-peptídeos
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
BR112017013765A2 (pt) métodos para uso de oligonucleotídeos antisense smad7
MY194135A (en) Treatment and diagnosis of inflammatory disorders
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112017028025A2 (pt) complexo de ferro-carboidrato para o tratamento da deficiência de ferro de um feto ou de um bebê
NZ712540A (en) Phenyl derivative having s1p2 antagonistic activity
EA201500765A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA201891922A1 (ru) Лекарственное средство для лечения инфекций на фоне диабетической стопы
EA202090024A1 (ru) Способы лечения лептоменингеального заболевания

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements